| Not Yet Recruiting | Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune R NCT05202288 | ANRS, Emerging Infectious Diseases | Phase 2 |
| Not Yet Recruiting | EBOla Post-Exposure Prophylaxis NCT06841614 | ANRS, Emerging Infectious Diseases | Phase 3 |
| Recruiting | REVIVE (Response to the Ebola Virus Vaccine) NCT05992480 | Tulane University | Phase 4 |
| Recruiting | Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vacc NCT06126822 | Institute of Tropical Medicine, Belgium | Phase 3 |
| Not Yet Recruiting | Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Bo NCT06587503 | University of Birmingham | Phase 4 |
| Active Not Recruiting | Immunology of Ebola Vaccine NCT06100913 | Emory University | Phase 2 |
| Unknown | Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central U NCT06093646 | MRC/UVRI and LSHTM Uganda Research Unit | N/A |
| Unknown | Community Preparedness for Outbreak Response and Readiness for Ebola Vaccination in Liberia NCT05888649 | UL-PIRE Africa Center | — |
| Completed | Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors NCT05494801 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Unknown | Prophylaxis Vaccine Antibodies Ebola NCT04822376 | ANRS, Emerging Infectious Diseases | Phase 2 |
| Completed | Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study NCT05064956 | London School of Hygiene and Tropical Medicine | Phase 2 |
| Completed | INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees NCT04906629 | University of Geneva, Switzerland | Phase 1 |
| Completed | Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study) NCT04711356 | London School of Hygiene and Tropical Medicine | Phase 2 |
| Completed | Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné NCT05130398 | Centre de Recherche Médicale de Lambaréné | Phase 1 / Phase 2 |
| Unknown | An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease NCT04717830 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Phase 1 |
| Unknown | Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC NCT04235361 | University of Stirling | — |
| Completed | Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults NCT04723602 | Albert B. Sabin Vaccine Institute | Phase 1 |
| Completed | Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola) NCT04409405 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Completed | Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola NCT04186000 | Universiteit Antwerpen | Phase 2 |
| Unknown | Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC NCT04152486 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Terminated | Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response NCT04250168 | Institute of Tropical Medicine, Belgium | — |
| Completed | A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants NCT03929757 | Janssen Vaccines & Prevention B.V. | Phase 2 |
| Completed | ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo) NCT04028349 | MRC/UVRI and LSHTM Uganda Research Unit | Phase 2 |
| Completed | EBOVAC-Salone Extension NCT03820739 | London School of Hygiene and Tropical Medicine | — |
| Completed | Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Vi NCT04815174 | Alliance for International Medical Action | — |
| Completed | Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine NCT03161366 | Epicentre | Phase 3 |
| Terminated | Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavir NCT03462004 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up NCT02431923 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term S NCT03098862 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi NCT03072030 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Phase 4 |
| Completed | Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines NCT03140774 | University of Oxford | — |
| Completed | Partnership for Research on Ebola VACcinations NCT02876328 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults NCT02718469 | Auro Vaccines LLC | Phase 1 |
| Completed | Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN NCT02509494 | Janssen Vaccines & Prevention B.V. | Phase 3 |
| Completed | A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV NCT02495246 | University of Oxford | Phase 1 |
| Completed | Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination NCT02485912 | University of Oxford | Phase 1 |
| Completed | A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization NCT02533791 | Jiangsu Province Centers for Disease Control and Prevention | Phase 1 |
| Terminated | A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z NCT02451891 | University of Oxford | Phase 1 |
| Unknown | Multiple Treatments for Ebola Virus Disease (EVD) NCT02380625 | Clinical Research Management, Inc. | Phase 1 / Phase 2 |
| Completed | Evaluation of the FilmArray BioThreat-E Test NCT02658331 | BioMérieux | — |
| Completed | Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO) NCT02368119 | University of Maryland, Baltimore | Phase 1 |
| Completed | A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China. NCT02401373 | First Affiliated Hospital of Zhejiang University | Phase 1 |
| Completed | Efficacy of Favipiravir Against Ebola (JIKI) NCT02329054 | Institut National de la Santé Et de la Recherche Médicale, France | Phase 2 |
| Unknown | A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kili NCT02296983 | University of Oxford | Phase 1 |
| Withdrawn | Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD NCT02307591 | Emergency NGO Onlus | Phase 2 / Phase 3 |
| Completed | A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. NCT02326194 | Jiangsu Province Centers for Disease Control and Prevention | Phase 1 |
| Unknown | Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment NCT02333578 | Clinical Research Management, Inc. | N/A |
| Completed | Efficacy of Favipiravir Against Severe Ebola Virus Disease NCT02662855 | Beijing Institute of Pharmacology and Toxicology | Phase 2 |
| Completed | Phase 1 Trial of Ebola Vaccine in Mali NCT02267109 | University of Maryland, Baltimore | Phase 1 |
| Withdrawn | An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola NCT04268966 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Evaluating an Ebola and a Marburg Vaccine in Uganda NCT00997607 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Ebola and Marburg Virus Vaccines NCT00605514 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Experimental Vaccine for Prevention of Ebola Virus Infection NCT00374309 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Available | R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease NCT03576690 | Regeneron Pharmaceuticals | — |
| Available | Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR NCT05067166 | Ridgeback Biotherapeutics, LP | — |